NEW BRUNSWICK, N.J., and BUFFALO, N.Y.

BUFFALO, N.Y.

Researchers at Roswell Park Comprehensive Cancer Center have garnered three of four grants awarded by the National Comprehensive Cancer Network Oncology Research Program to evaluate and define the clinical effectiveness of the investigational compound nintedanib, also known as BIBF 1120. These grants were made possible through general research funding provided to NCCN from Boehringer Ingelheim Pharmaceuticals Inc.

BUFFALO, N.Y. — A large collaborative study provides new evidence that African-American women may be able to significantly reduce their risk of developing aggressive forms of breast cancer by breastfeeding.

BUFFALO, N.Y. — A review article authored by two Roswell Park Comprehensive Cancer Center experts provides a comprehensive clinical view of currently available and novel MEK inhibitors, and highlights strategies that may lead to the wider use of these agents in cancer therapy.

BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center has once again been included on Becker’s Hospital Review’s “100 Hospitals and Health Systems With Great Oncology Programs,” an annual list of centers that are national leaders in patient care, cancer outcomes and research.